id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-1630-0007,FDA,FDA-2013-D-1630,"Draft Guidance for Industry on Qualification for the Use of
Galactomannan in Serum and Bronchoalveolar Lavage Fluid;
Availability",Notice,Notice of Availability,2014-10-27T04:00:00Z,2014,10,2014-10-27T04:00:00Z,2014-12-27T04:59:59Z,2015-10-15T18:28:52Z,2014-25532,0,0,09000064818feee7
FDA-2013-D-1630-0008,FDA,FDA-2013-D-1630,"Draft Guidance for Industry on Qualification for the Use of
Galactomannan in Serum and Bronchoalveolar Lavage Fluid",Other,Guidance,2014-10-27T04:00:00Z,2014,10,2014-10-27T04:00:00Z,,2024-11-07T23:09:40Z,,1,0,09000064818ff0ae
FDA-2013-D-1630-0001,FDA,FDA-2013-D-1630,"Draft Guidance for Industry on Qualification of Exacerbations of
Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute
Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic
Obstructive Pulmonary Disease; Availability",Notice,Notice of Availability,2014-01-10T05:00:00Z,2014,1,2014-01-10T05:00:00Z,2014-04-11T03:59:59Z,2020-04-27T19:25:04Z,2014-00259,0,0,09000064814fa97f
FDA-2013-D-1630-0002,FDA,FDA-2013-D-1630,Guidance on Qualification Process for Drug Development Tools Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease,Other,Guidance,2014-01-10T05:00:00Z,2014,1,2014-01-10T05:00:00Z,,2024-11-07T23:02:18Z,,1,0,09000064814fc520